Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Table 3 Summary of prior therapy

Characteristics	No. of patients	%
No. of chemotherapy regimens before gefitinib
1	2	18
2	4	36
3	4	36
4	1	9
Best response to gefitinib
PR	8	73
SD	3	27
PFS to gefitinib
Median	9.8
95% CI	6.6 - 16.7
Interval from discontinuation of gefitinib to 2^nd EGFR-TKI
Median	2.8
95% CI	1.9 - 6.9

ISSN: 1471-2407